Keywords:
CDKL5 deficiency disorder; biomarkers; epilepsy; healthcare; outcome assessment; quality of life
Abstract:
CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy (DEE) associated with multiple impairments and comorbidities. Outcome measures for disease-modifying clinical trials for DEEs should measurably capture a spectrum of caregiver priorities and be externally validated.